[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]
[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]
Z
Most Popular Now
GSK reaches agreement with Novartis to acquire ful…
GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...
Canadian neuroscientists say daily ibuprofen can p…
A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...
First proof a synthesized antibiotic is capable of…
A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...
Merck partners with Medisafe to help improve medic…
Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...
Phase III data in The Lancet show Novartis siponim…
Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...
Taking a standard prostate cancer drug with food b…
By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...
North and south cooperation to combat tuberculosis
Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...
New immunotherapy for lung cancer shows promise of…
In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...
Boehringer Ingelheim and OSE Immunotherapeutics an…
Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, have announced a collaboration and excl...
Personalized tumor vaccine shows promise in pilot …
A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...
Lokelma approved in the EU for the treatment of ad…
AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...
New targeted therapy schedule could keep melanoma …
Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...
Business & Industry
- FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
- Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
- Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
- Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
- GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Research & Development
- Personalized tumor vaccine shows promise in pilot trial
- New class of drugs could help tackle treatment-resistant cancers
- New immunotherapy for lung cancer shows promise of success
- Human drug trials are compromised by poor reporting of animal research
- 'Coffee filter' helps make new cancer drug Z-endoxifen 1,000 times cheaper
- Researchers propose key elements of antimicrobial stewardship for hospitals worldwide
- When drugs are wrong, skipped or make you sick: The cost of non-optimized medications
Conferences & Events
- SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast
- Introducing SMi's 6th annual conference on Pharmaceutical Freeze Drying Technology this June 2018
- Adaptive Designs in Clinical Trials Conference 2018
- Drug Safety 2018
- Controlled Release Delivery Conference 2018
- Superbugs & Superdrugs Conference 2018
- Highly Potent Active Pharmaceutical Ingredients (HPAPI) Conference 2018
Regulatory Affairs
- FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems
- FDA approves new treatment for certain digestive tract cancers
- FDA approves first treatment for breast cancer with a certain inherited genetic mutation
- FDA updates the label of Tasigna to reflect that certain patients with a type of leukemia may be eligible to stop treatment after sustained response
- FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss
- FDA launches new tool for sharing information that allows doctors to better manage antibiotic use; improve patient care
- FDA launches public education campaign to encourage adult smokers trying to quit cigarettes